Hepatitis C virus infection in patients receiving opiate substitution therapy in Sweden.

作者: Anna Jerkeman

DOI:

关键词:

摘要: The hepatitis C virus (HCV) is a blood borne effectively spread through injection practices. Consequently, people who inject drugs (PWID) are at the center of current HCV epidemic in industrialized countries, with regards both to prevalence and incidence. Through progressive liver fibrosis, chronic infection conveys substantial risk cirrhosis end-stage disease. These complications can be prevented by successful treatment resulting clearance. uptake has hitherto been low among PWID, due barriers on patient- as well health care provider levels. PWID also have multitude other factors affecting morbidity mortality. major causes death directly drug related. Opiate substitution therapy (OST) reduces related mortality heroin using which might allow for conditions, such infection, impact OST improves social functioning shown improve outcomes users, hence clinics could serve important points contact management. aim this thesis was investigate different aspects Swedish recipients. In cross-sectional multi study receiving patients Stockholm, Gothenburg Malmo we assessed burden severity fibrosis relation potential factors. We evaluated feasibility peginterferon/ribavirin based treatment, same cohort, special attention psychiatric status quality life (HRQoL). register exposure users recruited from needle exchange program. cohort found high rates (88% anti-HCV positive) 67% viremic showed significant association alcohol intake, elevated BMI B virus. treated subjects observed completion (83%) SVR (46%) line previous reports spite scores HRQoL occurrence depression already baseline. population program significantly (HR 3.08, 95%CI (1.09, 8.68), p=0.03) exposure. conclusion, disease problem may an increasingly common cause death. Thus, targeted management progression should integral part comprehensive provided clinics. Our findings satisfactory holds promise even higher once new interferon free regimens efficacy, less toxicity shorter duration, implemented. However, more efficient therapies able mortality, increasing assessment recipients essential

参考文章(198)
Kimberly Page, Meghan D. Morris, Judith A. Hahn, Lisa Maher, Maria Prins, Injection Drug Use and Hepatitis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention Clinical Infectious Diseases. ,vol. 57, ,(2013) , 10.1093/CID/CIT300
Barbara Rehermann, Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence Journal of Clinical Investigation. ,vol. 119, pp. 1745- 1754 ,(2009) , 10.1172/JCI39133
Martin Schaefer, Lucile Capuron, Astrid Friebe, Crisanto Diez-Quevedo, Geert Robaeys, Sergio Neri, Graham R. Foster, Achim Kautz, Daniel Forton, Carmine M. Pariante, Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. Journal of Hepatology. ,vol. 57, pp. 1379- 1390 ,(2012) , 10.1016/J.JHEP.2012.07.037
H. Hagan, E. R. Pouget, D. C. Des Jarlais, C. Lelutiu-Weinberger, Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place American Journal of Epidemiology. ,vol. 168, pp. 1099- 1109 ,(2008) , 10.1093/AJE/KWN237
Robert Thimme, Marco Binder, Ralf Bartenschlager, Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. Fems Microbiology Reviews. ,vol. 36, pp. 663- 683 ,(2012) , 10.1111/J.1574-6976.2011.00319.X
Georgina J. MacArthur, Eva van Velzen, Norah Palmateer, Jo Kimber, Anastasia Pharris, Vivian Hope, Avril Taylor, Kirsty Roy, Esther Aspinall, David Goldberg, Tim Rhodes, Dagmar Hedrich, Mika Salminen, Matthew Hickman, Sharon J. Hutchinson, Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness International Journal of Drug Policy. ,vol. 25, pp. 34- 52 ,(2014) , 10.1016/J.DRUGPO.2013.07.001
L. Graham, Sheila M. Bird, Sheila M. Bird, J.F. Dillon, P.R. Mills, S.A. McDonald, S.J. Hutchinson, D.J. Goldberg, C. Robertson, The growing contribution of hepatitis C virus infection to liver-related mortality in Scotland Eurosurveillance. ,vol. 15, pp. 19562- ,(2010) , 10.2807/ESE.15.18.19562-EN
J. Iversen, J. Grebely, L. Topp, H. Wand, G. Dore, L. Maher, Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 Journal of Viral Hepatitis. ,vol. 21, pp. 198- 207 ,(2014) , 10.1111/JVH.12129
Bart P. Grady, Janke Schinkel, Xiomara V. Thomas, Olav Dalgard, Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs Clinical Infectious Diseases. ,vol. 57, ,(2013) , 10.1093/CID/CIT301
Manfred Wiese, Frieder Berr, Michael Lafrenz, Heiner Porst, Ute Oesen, Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology. ,vol. 32, pp. 91- 96 ,(2000) , 10.1053/JHEP.2000.8169